Interpreting TRIPS: Globalisation of Intellectual Property Rights and Access to Medicines

Interpreting TRIPS: Globalisation of Intellectual Property Rights and Access to Medicines

Volumn , Issue , 2011, Pages 1-536

  Yamane, Hiroko ^a  

^a NATIONAL GRADUATE INSTITUTE FOR POLICY STUDIES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930451886     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (471)

1. WHO, The World Medicines Situation (Geneva, WHO, 2004), WHO/EDM/PAR/2004.5, 61-74: www.searo.who.int/LinkFiles/Reports_World_Medicines_Situation.pdf.
2. United Nations, Delivering on the Global Partnership for Achieving the Millennium Development Goals: MDG Gap Task Force Report 2008 (New York, United Nations, 2008) 36-43.
3. A Cameron, M Ewen, D Ross-Degnan, D Ball, R Laing, ‘Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis’, www.thelancet.com, published online December 2008.
4. ET Penrose, ‘International Patenting and the Less-Developed Countries’ (1973) 83 The Economic Journal 772.
5. P McCalman, ‘Who Enjoys TRIPs Abroad? An Empirical Analysis of Intellectual Property Rights in the Uruguay Round’ (2005) 38(2) Canadian Journal of Economics chs 2 and 11 of this book).
6. S Schweitzer, Pharmaceutical Economics and Policy, (Oxford University Press, 2007) ch 5.
7. G Velasquez, L’Industrie du médicament et le tiers monde (Paris, Edition l’Harmattan, 1983).
8. S Chaudhuri, ‘Ranbaxy Sell-out: Reversal of Fortunes, Economic & Political Weekly, 19 July 2008;
9. K Kubo and H Yamane, ‘Determinants of HIV/AIDS Drug Prices for Developing Countries: Analysis of Global Fund Procurement Data’ in H Uchimura (ed) Making Health Services More Accessible in Developing Countries: Finance and Health Resources for Functioning Health Systems (Palgrave MacMillan, 2009) 137-72.
10. www.ide.go.jp/English/Publish/Download/Jrp/pdf/142_05.pdf.
11. AB Jaffe and J Lerner, Innovation and Its Discontents: How Our Broken Patent System is Endangering Innovation and Progress and What to Do About It (Princeton University Press, 2004).
12. E Mansfield, ‘Patents and Innovation: An Empirical Study’ (1986) 32(2) Management Science 173-81.
13. DL Burk and MA Lemley, ‘Policy Levers in Patent Law’ (2003) University of California at Berkeley Law School Public Law & Legal Theory Research Paper Series, Research Paper No 135.
14. P Cuatrecasas, ‘Drug discovery in jeopardy’ (2006) 116 (11) Journal of Clinical Investigation 2837-42.
15. MA Lemley, ‘Reconceiving Patents in the Age of Venture Capital’ (2000) 4 Journal of Small and Emerging Business Law (Northwestern School of Law of Lewis & Clark College) 137, 139.
16. S Ladas, Patents, Trademarks & Related Rights: National & International Protection (Cambridge, Harvard University Press, 1975) vol I. 1-16.
17. European Patent Office (EPO), ‘About Patents’, www.epo.org/patents/Grant-procedure/Aboutpatents.html.
18. L Lessig, Free Culture: The Nature and Future of Creativity (New York, Penguin Press, 2004).
19. AB Jaffe and J Lerner, Innovation and Its Discontents: How Our Broken Patent System is Endangering Innovation and Progress, and What to Do About It (Princeton University Press, 2004).
20. Open Source Initiative (2006), Open Source Definition, available at http://opensource.org/docs/osd.
21. HW Chesbrough et al (eds), Open Innovation: Researching a New Paradigm (Oxford, Oxford University Press, 2006) 1.
22. SJ Liebowitz and R Watt, ‘How to Best Ensure Remuneration for Creators in the Market For Music? Copyright and its Alternatives’ (2006) 20(4) Journal of Economic Surveys 528.
23. J Stiglitz and J Sulston, ‘The Case Against Gene Patents’ The Wall Street Journal (New York, 16 April 2010).
24. www.monsanto.com/monsanto/ag_products/input_traits/products/roundup_ready_soybeans.asp.
25. www.patentlens.net/daisy/bios/3541/version/default/part/AttachmentData/data/CAMBIA%20PMET%20BiOS%20agreement.pdf.
26. S Scotchmer, ‘Standing on the Shoulders of Giants: Cumulative Research and the Patent Law’ (1991) 5(1) Journal of Economic Perspectives 30.
27. BD Wright, ‘The Economics of Invention Incentives: Patents, Prizes, and Research Contracts’ (1983) 73(4) The American Economic Review 691-707.
28. A Arora, ‘Licensing Tacit Knowledge: Intellectual Property Rights and the Market for Know-how’ (1995) 4 Economics of Innovation and New Technology 41-59.
29. JI Bulow, JD Geanakoplos and PD Klemperer, ‘Multimarket Oligopoly: Strategic Substitute and Complements’ (1985) Journal of Political Economy (https://faculty-gsb.stanford.edu/bulow/articles/Multimarket%20Oligopoly.pdf).
30. A Arora, A Fosfuri and A Gambardella, Markets for Technology (Cambridge, MIT Press, 2001);
31. A Arora and M Ceccagnoli, ‘The role of patent protection and commercialization capabilities’ (2006) 52(2) Management Science 293-308.
32. E Mansfield et al, ‘Imitation Costs and Patents: An Empirical Study’ (1981) 91 The Economic Journal 907-18.
33. NT Gallini, ‘Patent Policy and Costly Imitation’ (1992) 23(1) RAND Journal of Economics (RJE);
34. L DeBrock, ‘Market Structure, Innovation, and Optimal Patent Life’ (1985) 28(1) Journal of Law and Economics;
35. W Nordhaus, ‘The Optimum Life of a Patent: Reply’ (1969) 62(3) American Economic Review.
36. FM Scherer, ‘Nordhaus Theory of Optimal Patent Life: A Geometric Reinterpretation’ (1972) 62(3) American Economic Review.
37. P Klemperer, ‘How Broad should the Scope of Patent Protection Be?' (1990) 21 RJE 113-30.
38. R Gilbert and C Shapiro, ‘Optimal Patent Length and Breadth’ (1990) 1 RJE 106-12.
39. C Shapiro, ‘Antitrust Limits to Patent Settlements’ (2003) 34(2) RJE 391-411.
40. MA Lemley and C Shapiro, ‘Probabilistic Patents’ (2005) 19(2) The Journal of Economic Perspectives 75-95.
41. JR Green and S Scotchmer, ‘On the Division of Profit in Sequential Innovation’ (1995) 26(1) RJE 20-33.
42. V Denicolo, ‘Two-Stage Patent Races and Patent Policy’ (2000) 31(3) RJE 488-501.
43. E O’Donoghue, ‘A Patentability Requirement for Sequential Innovation’ (1998) 29(4) RJE 657.
44. JA Schumpeter, Capitalism, Socialism and Democracy (London, Routledge, 1994; originally published by Allen & Unwin, 1942).
45. K Arrow, ‘Economic Welfare and the Allocation of Resources for Invention’, in RR Nelson (ed), The Role and Direction of Inventive Activity (Princeton NJ, Princeton University Press, 1962).
46. J Gilbert and DMG Newbery, ‘Preemptive patenting and the persistence of monopoly’ (1982) 72 Arnerican Economic Review 514-26.
47. J Reiganum, ‘Uncertain innovation and the persistence of monopoly’ (1983) 73 American Economic Review 741-48.
48. RE Caves and ME Porter, ‘From Entry Barriers to Mobility Barriers: Conjectural Decisions and Contrived Deterrence to New Competition’ (1977) 91(2) The Quarterly Journal of Economics 241-61.
49. S Salop ‘The Noisy Monopolist: Imperfect Information, Price Dispersion, and Price Discrimination’ (1977) 44 Review of Economic Studies 393.
50. P Aghion and R Griffith, Competition and Growth: Reconciling Theory and Evidence (Cambridge MA, MIT Press, 2005).
51. O Williamson, Allocative Efficiency and the Limits of Antitrust (1969) May American Economic Review Papers & Proceedings 105-118;
52. H Hovenkamp, Antitrust Policy After Chicago, (1985) 84 Michigan Law Review 213;
53. H-D Ehlermann and L Laudati (eds), European Competition Law Annual 1997: Objectives of Competition Policy (Oxford, Hart Publishing, 1998).
54. S Ladas, Patents, Trademarks & Related Rights: National & International Protection (Cambridge MA, Harvard University Press, 1975) 1-16
55. www.wipo.int/treaties/en/index.jsp.
56. ET Penrose, ‘International Patenting and the Less-Developed Countries’ (1973) 83 The Economic Journal 768.
57. GHC Bodenhausen, Guide to the Application of the Paris Convention for the Protection of Industrial Property as revised at Stockholm in 1967 (Geneva, BIRPI, 1968) (reprinted in 2007).
58. R. Ayyangar, Report on the Revision of the Patent Law (New Delhi, 1959).
59. J Mueller, ‘The Tiger Awakens: The Tumultuous Transformation of India’s Patent System and the Rise of Indian Pharmaceutical Innovation’ (2007) 68(3) University of Pittsburgh Law Review 576.
60. FM Scherer, ‘The Economic Effects of Compulsory Licences’ (New York, University Monograph Series in Finance and Economics 1977-2 (1977)) 40-5.
61. BIRPI, Model Law for Developing Countries on Inventions, Publication No 801(E) (Geneva, 1965).
62. H Iwata et al, Busshitsu no Chishiki (‘Knowledge about Product Patents’) (Tusho-Sangyo Chosakai, 1975) 83-91;
63. H Redwood, New Horizons in India: the Consequences of Pharmaceutical Patent Protection (Felixstowe, Oldwicks Press, 1994) 91-7.
64. K Murayama, ‘Nihon ni okeru busshitsu iyakutokkyoseido donyu no keiken ni tshuite’ (‘On the Experience of Product and Pharmaceutical Patent Introduction in Japan’) (1983) 33(10) Tokkyo Kanri 1261-71.
65. United Nations, The Role of Patents in the Transfer of Technology to Developing Countries: Report of the Secretary-General, UN Publication Sales No 65.II.B.1 (New York, 1964) (1964 UN Report).
66. S J Patel, P Roffe and A Yusuf, International Technology Transfer - The Origins and Aftermath of the United Nations Negotiations on a Draft Code of Conduct, Kluwer Law International (The Hague, 2001) 3 et seq 259 et seq;
67. P Roffe, ‘Transfer of Technology: UNCTAD’s Draft International Code of Conduct’, (1985) 19 The International Lawyer 689.
68. P Roffe and G Vea, ‘The WIPO Development Agenda in an Historical and Political Context’, in NW Netanel (ed.) The Development Agenda: Global Intellectual Property and Developing Countries (Oxford, Oxford University Press, 2009) 99-109.
69. E Penrose, The Economics of the International Patent System (Baltimore MD, The Johns Hopkins University Press, 1951);
70. HE Grundmann, ‘Patent Laws in New African States’ (1968) 50(7) Journal of the Patent Office Society 486-503;
71. RE Baldwin and JD Richardson, ‘Other Issues: North-South Trade, IPRs, and Subsidies’ (1986) Issues in the Uruguay Round, NBER Conference Report;
72. A Jaffe, ‘Technological Opportunity and Spillovers of R&D’ (1988) 76 American Economic Review 984-1001.
73. HE Grundmann, ‘Foreign patent monopolies in developing countries: An empirical analysis’ (1976) 12(2) Journal of Development Studies 186-96.
74. R Vernon, Sovereignty at Bay: The Multinational Spread of US Enterprises (New York, Basic Books, 1971) 107.
75. CV Vaitsos, ‘Patents Revisited: Their Function in Developing Countries’ (1972) 9 Journal of Development Studies.
76. C T Tayler and ZA Silbertson, The Economic Impact of the Patent System (Cambridge, Cambridge University Press, 1973).
77. K Grefermann and KC Rothlingshofer, Patentwesen und technischer Fortschritt (Gottingen, Verlag Otto Schwarz & Co, 1974) vol II.
78. FM Scherer, The Economic Effects of Compulsory Patent Licensing (New York, New York University, 1977) 58-9.
79. JY Lee and E Mansfield ‘Intellectual Property Protection and US Foreign Direct Investment’ (1996) 78(2) The Review of Economics and Statistics 181-6.
80. PJ Smith, ‘How do foreign patent rights affect U.S. exports, affiliate sales, and licenses?' (2001) 55 Journal of International Economics (J Int Econ) 411-39.
81. JY Lee and E Mansfield, ‘Intellectual Property Protection and US Foreign Direct Investment’ (1996) 78(2) The Review of Economics and Statistics 181-6.
82. WG Park and DC Lippoldt, ‘Technology Transfer and the Economic Implications of the Strengthening of Intellectual Property Rights in Developing Countries’ (2008) OECD Trade Policy Working Paper No 62.
83. JC Chin and GM Grossman,‘IPRs and North-South Trade’ (1988) NBER Working Paper Series, Working Paper No 2769.
84. I Diwan and D Rodrik, ‘Patents, appropriate technology, and North-South trade’ (1991) 30 Journal of International Economics 27-47
85. A Arora and A Gambardella, ‘Domestic Markets and International Competitiveness: Generic and Product-specific Competencies in the Engineering Sector’ (1997) 18 Strategic Management Journal 53-74.
86. GM Grossman and ELC Lai, ‘International Protection of Intellectual Property’ (2004) 94(5) The American Economic Review 1635-53.
87. United Nations Conference on Trade and Development (UNCTAD), ‘Changing Dynamics of Global Computer Software and Service Industry: Implications for Developing Countries’ (2002) 12, Technology for Development Series, www.unctad.org/en/docs/psitetebd12.en.pdf.
88. P McCalman, ‘Who Enjoys TRIPs Abroad? An Empirical Analysis of Intellectual Property Rights in the Uruguay Round’ (2005) 38(2) Canadian Journal of Economics 574-603.
89. J Straus, ‘Biotechnology and Patents’ (2000) 54 Chimia 298.
90. J Watal, ‘Intellectual property and biotechnology: trade interests of developing countries’ (2000) 2(1/2/3) International Journal of Biotechnology 51.
91. CM Correa, ‘Patenting Human DNA: What Flexibilities Does the TRIPS Agreement Allow?' (2007) 10 Journal of World Intellectual Property 419.
92. K Kawakami and H Yamane, ‘Clinical Research in Japan: Ways to Alleviate Unnecessary Regulatory Burdens’ (2007) 1(1) RECIIS 57-61, http://www.reciis.cict.fiocruz.br/index.php/reciis/.
93. MP Feldman et al, ‘Lessons from the Commercialization of the Cohen-Boyer Patents: The Stanford University Licensing Program, 2007 http://www.iphandbook.org/handbook/chPDFs/ch17/ipHandbook-Ch%2017%2022%20Feldman-Colaianni0Liu%20Cohen-Boyer%20Patents%20and%20Licenses.pdf.
94. Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS), ‘Report on Gene Patents and Licensing Practices and their Impact on Patient Access to Genetic Tests’ (5 February 2010) 24-6.
95. BIO presentation on the 2009 Member Survey, Technology Transfer and the Biotechnology Industry, available at http://bio.org/ip/techtransfer/PDF.TECH.TRANSFER.PRESENTATION.10.25.pdf.
96. H-R Jaenichen, Biotechnology Law Report (1996) 15(6) 883-91.
97. N Pires de Carvalho, ‘The Problem of Gene Patents’ (2004) 3 Washington University Global Studies Law Review 701-23;
98. The TRIPS Regime of Patent Rights, 3rd edn (Alphen aan den Rijn, Kluwer Law International, 2010) 252-65.
99. S J R Bostyn, ‘Patenting DNA sequences (polynucleotides) and scope of protection in the European Union: an evaluation’ (European Commission; Directorate-General for Research Food Quality and Safety, 2004) 6.
100. P Richardson, ‘EMEA Regulatory Approaches to Biosimilars and Guidelines’ Graduate Institute for Policy Studies (GRIPS) International Conference on ‘Biotech Medicines Innovations in Developing Countries: Intellectual Property Protection and Regulations for Safety and Efficacy’, 19 February 2009 www.grips.ac.jp/docs/richardson.pdf.
101. www.grips.ac.jp/docs/090219.html.
102. PK Ghosh, ‘Indian Efforts for Developing Biotechnology’ (2008) 11(1) Asian Biotechnology and Development Review, 41.
103. http://app1.sfda.gov.cn/datasearch/face3/dir.html.
104. www.grips.ac.jp/docs/silva.pdf.
105. USPTO www.uspto.gov/web/menu/busmethp/class705.htm#top.
106. WIPO Report, ‘Intellectual Property on the Internet: A Survey of Issues’ (2002), www.wipo. int/copyright/en/ecommerce/ip_survey/chap3.html#_ftnref356.
107. J Stiglitz and J Sulston ‘The Case Against Gene Patents’ The Wall Street Journal (New York, 16 April 2010).
108. ‘USDOJ Files Brief Opposing Gene Patents’, (1 November 2010) GenomeWeb News (New York).
109. MA Heller and RS Eisenberg, ‘Can Patents Deter Innovation? The Anticommons in Biomedical Research’ (1998) 280(5364) Science 698-701.
110. DC Mowery, RR Nelson, BN Sampat and AA Ziedonis, ‘The growth of patenting and licensing by US universities: An assessment of the effects of the Bayh-Dole Act of 1980' (2001) 30 Research Policy 99-119;
111. RR Nelson ‘The market economy, and the scientific commons’ (2004) 33(3) Research Policy 455-71;
112. PA David, ‘Can “Open Science” be Protected from the Evolving Regime of IPR Protections?' (2004) 160(1) Journal of Institutional and Theoretical Economics 9-34.
113. JM Mueller, ‘No “Dilettante Affair”: Rethinking the Experimental Use Exception to Patent Infringement for Biomedical Research Tools’ (2001) 76 Washington Law Review. 1, 52, fn 255.
114. W Cohen and J Walsh ‘Research Tool Patent and Licensing and Biomedical Innovation,' in Cohen and Merrill (eds), Patents in the Knowledge-based Economy (Washington DC, National Academies Press, 2003) 285-340;
115. SA Merrill and AM Mazza, Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health (Washington DC, National Academies Press, 2006).
116. A Odell-West, ‘The Legacy of Myriad for gene-based diagnostics: a new policy and regulatory option’ 2009 4(4) Journal of Intellectual Property Law & Practice 267-77.
117. www.jpo.go.jp/shiryou_e/s_sonota_e/fips_e/pdf/france_e/e_chiteki_zaisan.pdf.
118. ‘Special Legislation for Genetic Inventions - A Violation of Article 27(1) TRIPS?' in WPW Pyrmont et al (eds), Patents and Technological Progress in a Globalized World: Liber Amicorum Joseph Straus (MPI Studies on Intellectual Property, Competition and Tax Law, Berlin and Heidelberg, Springer, 2007) 293.
119. M Kock, ‘Purposebound protection for DNA sequences: in through the back door?' (2010) 5(7) Journal of Intellectual Property Law & Practice 496-7.
120. R Peet et al, ‘The Potential Impact of Monsanto Technology LLC v Cefetra et al on Patent Infringement’, (2010) IP Watch, 17 August.
121. President’s Commission on Industrial Competitiveness, Global Competition: The New Reality (Washington DC, US Government Printing Office, 1985).
122. SK Sell, Private Power, Public Law (Cambridge University Press, 2003);
123. MP Ryan, Knowledge Diplomacy: Global Competition and the Politics of Intellectual Property (Washington DC, Brookings Institution Press, 1998) 78-9.
124. S Takakura, Recent Development of Multilateral Agreements on Intellectual Property Rights (Tokyo, Yuhikaku, 2001) 153.
125. R Mazzoleni and RR Nelson, ‘The benefits and costs of strong patent protection: a contribution to the current debate’ (1998) 27(3) Research Policy, 30% of judgments held patents to be valid before the creation of the CAFC;
126. RA Schwartsman ‘Assertion of the Doctrine of Equivalents in Biotechnology Litigation: About as Successful as in Other Arts’ (2005) 17(12) Intellectual Property & Technology Law Journal.
127. T Cottier, ‘The Prospects for Intellectual Property in GATT’ (1991) 28 Common Market Law Review 385.
128. GE Evans, Lawmaking under the Trade Constitution: A Study in Legislating by the World Trade Organization (The Hague London, Boston, Kluwer Law International, 2000) 108-10.
129. R Cooper Dreyfuss, ‘TRIPS Round II: Should Users Strike Back?' (2004) 71(1) The University of Chicago Law Review 21.
130. D Gervais, The TRIPS Agreement: Drafting History and Analysis (London, Sweet & Maxwell, 1998) 10.
131. D Hartridge and A Subramanian, ‘Intellectual Property Rights: The Issues in GATT’ (1989) 22 Vanderbilt Journal of Transnational Law 893-910.
132. ‘India accepts principle of policing trade-related intellectual property’ (1989) 3 World Intellectual Property Report 244-5.
133. S Takakura, Chiteki Zaisan Housei to Kokusai Seisaku (IP Laws and International Policy, in Japanese) (Tokyo, Yuhikaku, 2001) 147.
134. JJ Gorlin, An analysis of the Pharmaceutical-related Provisions of the WTO TRIPS (IP) Agreement (Washington DC, IP Institute, 1999) 17-18.
135. N Pires de Carvalho, The TRIPS Regime of Antitrust and Undisclosed Information, ((The Hague, London, Boston, Kluwer Law International, 2008) 161-187;
136. E Gellhorn et al. Antitrust Law and Economics in a Nutshell (fifth edn) (St Paul, MN, West Publishing, 2004) 502-503.
137. J Watal, Intellectual Property Rights in the WTO and Developing Countries (The Hague, London, Boston, Kluwer Law International, 2001) 35.
138. J Straus, ‘TRIPS Agreement and Access to Medicines’, Annual Meeting of the Japanese Intellectual Property Association, Tokyo, 14 February 2003.
139. Q Schiermerier, ‘Germany challenges human stem cell patent awarded “by mistake”' (2000) 404 Nature 3-4.
140. www.epo.org/patents/law/legal-texts/html/guiex/e/c_iv_4_1.htm.
141. Panel Report, Thailand-Restrictions on Importation of and Internal Taxes on Cigarettes, adopted 7 November 1990, BISD 37S/200.
142. FM Scherer, Competition Policy, Domestic and International (Cheltenham, Edward Elgar, 2000) 327-42.
143. A Attaran and P Champ, ‘Patent Rights and Local Working under the WTO TRIPS Agreement: An Analysis of the U.S.-Brazil Patent Dispute’ 27 Yale Journal of International Law 365-80.
144. JC Ross and JA Wasserman, ‘Trade-Related Aspects of Intellectual Property Rights’, in TP Stewart (ed), The GATT Uruguay Round: A Negotiating History (1986-1992), Vol II (Kluwer Law and Taxation Publishers, Deventer, Boston, 1993) 2295-6
145. M Blakeney, Trade Related Aspects of Intellectual Property Rights: A Concise Guide to the Trips Agreement (London, Sweet & Maxwell, 1996) 89.
146. F-K Beier, ‘Exclusive Rights, Statutory Licenses and Compulsory Licenses in Patent and Utility Model Law’ (1999) 30, Int’l Review of Industrial Property and Copyright Law (IIC) 251-63.
147. T Cook, The Protection of Regulatory Data in the Pharmaceutical and Other Sectors (London, Sweet & Maxwell, 2000).
148. CM Correa, Protection of Data Submitted for the Registration of Pharmaceuticals:Implementing the Standards of the TRIPS Agreement (Geneva, South Center, 2002);
149. R Dinca, ‘The “Bermuda Triangle” of Pharmaceutical Law: Is Data Protection a Lost Ship?' (2005) 8(4) Journal of World Intellectual Property 517-63.
150. A Taubman, ‘Unfair competition and the financing of public-knowledge goods: the problem of test data protection’ (2008) 3(9) Journal of Intellectual Property Law & Practice 601.
151. JH Reichman, ‘Undisclosed Clinical Trial Data Under the TRIPS Agreement and Its Progeny:A Broader Perspective’, UNCTAD-ICTSD Dialogue on Moving the pro-development IP agenda forward: Preserving Public Goods in health, education and learning, Bellagio, 29 November-3 December 2004, 4.
152. H Bale, ‘Drug, Textile Makers to Fight Trade Pact’, Journal of Commerce, 8 January 1992.
153. H Redwood, New Horisons in India: the consequences of pharmaceutical patent protection, (Felixstowe, Oldwicks Press, 1994) 39.
154. F Gurry, ‘A Multilateral View of Change in the Patent System’, OECD Conference on IPR, Innovation and Economic Performance, Paris (October 2003) ch 22 p 334.
155. J Pauwelyn, ‘WTO dispute settlement: Of sovereign interests, private rights and public goods’, in KE Maskus and JH Reichman (eds), International Public Goods and Transfer of Technology under a Globalized Intellectual Property Regime (Cambridge, 2005) 817 et seq.
156. H Redwood, Where is the Pharma Industry Going? Insights for the New Millennium (Felixstowe, Oldwicks Press, 2002) 123.
157. A Otten and H Wager, ‘Compliance with TRIPS: the Emerging World View’, (1996) 29 Vanderbilt J Trans Law 391.
158. M Bronckers, ‘The Exhaustion of Patent Rights under World Trade Organization Law’ (1998) 32 Journal of World Trade Law;
159. F-K Beier, ‘Exclusive Rights, Statutory Licenses and Compulsory Licenses in Patent and Utility Model Law’ (1999) 30(3) IIC 254.
160. www.uspto.gov/web/offices/pac/mpep/documents/2100_2164.htm.
161. PW Grubb, Patents for Chemicals, Pharmaceuticals and Biotechnology: Fundamentals of Global Law, Practice and Strategy, 4th edn (Oxford University Press, 2004) 258-61.
162. UNCTAD-ICTSD, Resource Book on TRIPS and Development, (Cambridge University Press, 2005) 497-98
163. A Oshima, Chikujou Kaisetu TRIPS Kyoutei (Detailed Analysis of the TRIPS) (Tokyo, JMC, 1999) 163-64.
164. D Gervais, The TRIPS Agreement: Drafting History and Analysis (London, Sweet & Maxwell, 1998) 172.
165. P Samuelson and S Scotchmer, ‘The Law and Economics of Reverse Engineering’ (2002) 111(7) The Yale Law Journal 1575-1663.
166. American Law Institute, Restatement of the Law (Third), Unfair Competition (1995).
167. H Hovenkamp, MD Janis and MA Lemley, IP and antitrust: an analysis of antitrust principles applied to intellectual property law (Aspen Law & Business, 2002) App B-34.
168. J Pauwelyn, Conflict of Norms in Public International Law (Cambridge University Press, 2003).
169. RG Wetzel (compilation), D Rauschuning (ed), Dokumente, The Vienna Convention of the Law of Treaties: travaux préparatoires (Frankfurt am Main, Alfred Metzner Verlag, 1978).
170. McNair, Law of Treaties (1961) 366
171. C Rousseau, Principes généraux du droit international public (1944) 676 et seq
172. C de Visscher, Problèmes d’interprétation judiciaire en droit international public (1963) 50 et seq.
173. F Jacobs, ‘Varieties of Approach to Treaty Interpretation: With Special Reference to the Draft Convention on the Law of Treaties before the Vienna Diplomatic Conference’ (1969) 18(2) ICLQ 318-46.
174. G Schwarzenberger, International Law as Applied by International Courts and Tribunals 3rd edn (London, Stevens, 1957) 503.
175. ‘Statement of Professor Myres S McDougal, United States Delegation to Committee of the Whole’, (1968) 62 American Journal of International Law 1021.
176. J Klabbers, ‘Some Problems regarding the Object and Purpose of Treaties’ (1999) Finnish Yearbook of International Law, 138-60;
177. I Buffard and K Zemarek, ‘The object and purpose of a Treaty; an Enigma’ (1998) 3 Austrian Review of International and European Law 311-43,.
178. I Sinclair, The Vienna Convention on the Law of Treaties, 2nd edn (Manchester University Press, 1984) 130-1.
179. RG Wetzel (ed), The Vienna Convention of the Law of Treaties:Travaux Préparatoires (Vienna, Alfred Metzner Verlag GmbH, 1978) 239.
180. R Higgins, ‘Time and the Law’ (1997) 46 International and Comparative Law Quarterly 516.
181. JG Merrills, The Development of International Law by the European Court of Human Rights, 2nd edn (Manchester University Press, 1995).
182. J Pauwelyn, ‘The nature of WTO obligations’ (2002) Jean Monnet Working Paper 1/02, New York University School of Law.
183. JH Jackson, ‘The WTO Dispute Settlement System after Ten Years: The First Decade’s Promises and Challenges in The WTO’ in Y Taniguchi et al (eds) The Twenty-First-Century: Dispute Settlement, Negotiations, and Regionalism in Asia (Cambridge, Cambridge University Press 2007) 32-3.
184. Harris, Cases and Materials on International Law, 4th edn (1991);
185. Jiménez de Aréchaga, ‘International Law in the Past Third of a Century’ (1978) I Recueil des Cours;
186. Sinclair, The Vienna Convention and the Law of Treaties, 2nd edn (1984);
187. Jennings and Watts (eds), Oppenheims’ International Law, 9th edn (1992) vol I;
188. P Krugman, ‘What Should Trade Negotiators Negotiate About?' (1997) 35(1) Journal of Economic Literature 113-20.
189. PC Mavroidis and D Palmeter, ‘The WTO Legal System: Sources of Law’ (1998) 92 American Journal of International Law 411-12.
190. H Norn and JHH Weiler, ‘EC-Trade Description of Sardines: Textualism and its Discontent’ in H Horn and PC Mavroidis (eds), The WTO Case of 2002 (Cambridge University Press, 2005).
191. C Valles, ‘Challenges in interpreting Schedules of Concessions relying on the rules of treaty interpretation in the Vienna Convention on the Law of Treaties’, Sixth Annual WTO Conference, London, 23 May 2006.
192. F Ortino, ‘Treaty Interpretation and the WTO Appellate Body Report in US-Gambling:A Critique’ (2006) 9(1) Journal of International Economic Law 117-48.
193. D Shanker, ‘The Vienna Convention on the Law of Treaties: the dispute settlement system of the WTO and the Doha Declaration on the TRIPS Agreement’ (2002) 36(4) Journal of World Trade 721-72.
194. M Matsushita, TJ Schoenbaum and PC Mavroidis. The World Trade Organization: Law, Practice, and Policy, 2nd edn (Oxford University Press, 2006) 52.
195. JG Merrills, The Development of International Law by the European Court of Human Rights, 2nd edn (Manchester University Press, 1995) 98 et seq.
196. www.wipo.int/clea/en/text_pdf.jsp?lang=EN&id=515.
197. JJ Gorlin, An Analysis of the Pharmaceutical-related Provisions of the WTO TRIPS (IP) Agreement (IP Institute, 1999) 23.
198. A Attaran and P Champ, ‘Patent Rights and Local Working Under the WTO TRIPS Agreement:An Analysis of the U.S.-Brazil Patent Dispute’ (2002) 27 Yale Journal of International Law 365-80.
199. C Passarelli and T Veriano Jr, ‘Good Medicine: Brazil’s Multifront War on AIDS’ (2001) 35(5) NACLA Report on the Americas 35-52.
200. GB Dinwoodie and R Cooper Dreyfuss, ‘International Intellectual Property Law and the Public Domain of Science’ (2004) 7 Journal of International Economic Law 431-48.
201. F Abbott ‘The TRIPS-legality of measures taken to address public health crises: Responding to USTR-State-industry positions that undermine the WTO’ in RE Hudec, JD Southwick and DLM Kennedy (eds) The Political Economy of International Trade Law: Essays in Honour of Robert E Hudec (Cambridge University Press, 2002) 326.
202. K Maskus, ‘Differentiated Intellectual Property Regimes for Environmental and Climate Technologies’ (2009) OECD Working Party on National Environmental Policies ENV/EPOC/WPNEP6 para 49, 15-16.
203. DL Burk and MA Lemley, ‘Is Patent Law Technology-Specific?' (2002) 17 Berkeley Tech. Law Journal.
204. JH Barton, ‘United States Law of Genomic and Post-Genomic Patents’ (2002) 33 International Review of Industrial Property and Copyright Law.
205. WPW Pyrmont, ‘Special Legislation for Genetic Inventions-A Violation of Article 27(1) TRIPS?', in WPW Pyrmont et al (eds), Patents and Technological Progress in a Globalized World: Liber Amicorum Joseph Straus (MPI Studies on Intellectual Property, Competition and Tax Law, Berlin and Heidelberg, Springer, 2007) 209.
206. L Montagnier et al, ‘Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS)' (1983) 220 Science 868-71.
207. R C Gallo et al, ‘Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS’ (1984) 224 Science 500-3.
208. L Montagnier et al, ‘T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV’ (1984) 312 Nature 67-768;
209. F Clavel, ‘Deficient LAV1 Neutralising Capacity of Sera from Patients with AIDS or Related Syndromes’ (1985) 325 The Lancet 879-80.
210. B Seytre, L’Histoire de la recherche sur le SIDA (Que sais-je? no 3024) (Paris, Presses Universitaires de France, 1995).
211. JP Horowitz et al, ‘Nucleosides. V. The Monomesylates of 1-(2-Deoxy-O-D-lyxofuranosyl) thymine’ (1964) 29 The Journal of Organic Chemistry 2076-78.
212. E de Clercq et al, ‘Antiviral, antimetabolic and antineoplastic activities of 2- or 3-amino or -azido-substituted deoxyribonucleosides’ (1980) 29 Biochemical Pharmacology 1849-51.
213. H Mitsuya et al, '3-azido-3-deoxythymidine (BW A509U): An Antiviral Agent that Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus in vitro’ (1985) 82 Proceedings of National Academy of Sciences 7096-100.
214. Department of Health and Human Services (DHHS) http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
215. MS Hirsch et al, ‘Antiretroviral Drug resistance testing in Adults with HIV Infection:Implications for Clinical Management’ (1998) 279(24) Journal of the American Medical Association (JAMA), 41.
216. Hirsh et al, ‘Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel’, www.jkaids- stiftung.de/news/pdf/Hirsch-CID.pdf.
217. SM Hammer et al, ‘Antiretroviral Treatment of Adult HIV Infection. 2008 Recommendations of the International AIDS Society-USA Panel’ (2008) 300(5) JAMA 555-70.
218. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
219. R C Gallo and L Montagnier, ‘Un vaccin préventif efficace demandera encore bien des années de recherches: Nos propositions pour le sida’ Le Figaro, 2 June 2003, 14;
220. ‘Drug-resistant AIDS: the next tsunami’ Turkish Daily News, April 2006;
221. R Sutthenta et al, ‘HIV-1 drug resistance in Thailand:Before and after National Access to Antiretroviral Program’ (2005) 34 Journal of Clinical Virology 272-6;
222. S Sungkanuparph et al, ‘Options for a Second-Line Antiretroviral Regimen for HIV Type 1 Infected Patients Whose Initial Regimen of a Fixed-Dose Combination of Stavudine, Lamivudine, and Nevirapine Fails’ (2007) 44 Clinical Infectious Diseases 447-52;
223. S Sirivichayakul et al, ‘HIV drug resistance transmission threshold survey in Bangkok’ (2008) 2 Antiviral Therapy 109-13.
224. R McEnery, ‘If effective, pre-exposure prophylaxis for HIV will offer many opportunities, but also numerous challenges’ (2008) 12(6) IAVI Report, www.iavireport.org/archives/2008/Pages/IAVIReport12(6)PrEP-Work.aspx.
225. VA Johnson et al, ‘Update of the Drug Resistance Mutations in HIV-1' (2008) 138 International AIDS Society-USA Topics in HIV Medicine, www.iasusa.org/pub/topics/2008/issue5/138.pdf.
226. http://napwa.org.au/pl/2008/09/aids-2008-is-the-hiv-drug-pipeline-drying-up.
227. http://www.cid.harvard.edu/cidinthenews/articles/ap_042001.html.
228. PM Danzon ‘At what price?' (2007) 449 Nature 176-9.
229. SO Schweitzer, Pharmaceutical Economics and Policy, 2nd edn (Oxford University Press, 2007).
230. H K Lashman, ‘Pharmaceuticals in the Third World: An Overview’, PHN Technical Note 86-31, Population, Health and Nutrition Department, World Bank, November 1986 (1986 World Bank Report).
231. OECD, Health Data 2008. www.oecd.org/document/27/0,3343, en_2649_34631_40902299_1_1_1_1,00.html.
232. O Quist-Arcton, ‘South Africa: Battle Against Pharmaceutical Giants Continues’ 17 April 2001, http://allafrica.com/stories/200104170346.html.
233. SK Sell and A Prakash, ‘Using Ideas Strategically: The Contest Between Business and NGO Networks’ (2004) 8(1) Intellectual Property Rights, International Studies Quarterly 143-75.
234. ‘Africa’s AIDS War’, New York Times (10 March 2001).
235. KS Jayaraman, ‘Taste of their own medicines’, New Scientist (31 March 2001).
236. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm086187.pdf.
237. www.unaids.org/en/AboutUNAIDS/Secretariat/default.asp.
238. www.who.int/mediacentre/factsheets/fs278/en/index.html.
239. www.who.int/mediacentre/factsheets/fs278/en/.
240. R Laing et al, '25 Years of the WHO Essential Medicines Lists: Progress and Challenges’ (2003) 361 The Lancet 1723-29.
241. A Attaran and L Gillespie-White, ‘Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?' (2001) 286 JAMA.
242. www.cptech.org/ip/health/africa/dopatentsmatterinafrica.html.
243. WIPO, Patent Protection and Access to HIV/AIDS Pharmaceuticals in Sub-Saharan Africa (International Intellectual Property Institute, 2000) www.wipo.int/about-ip/en/studies/pdf/iipi_hiv. pdf.
244. www.un.org/News/dh/latest/sg_20010627.htm.
245. G Velasquez, l’Industrie du medicament et le tiers monde (Paris, Edition l’Harmattan, 1983) 93-94.
246. N Homedes et al, ‘The World Bank, Pharmaceutical Policies, and Health Reforms in Latin America’ (2005) 35(4) International Journal of Health Services 691-717.
247. P Cuatrecasas, ‘Drug discovery in jeopardy’ (2006) 116(11) Journal of Clinical Investigation 2837-42.
248. www.who.int/gb/EB_WHA/PDF/WHA52/e19.pdf.
249. SK Sell, Private Power, Public Law: The Globalization of Intellectual Property Rights (Cambridge Studies in International Relations, 2003) 149.
250. www.wto.org/english/news_e/news01_e/trips_drugs_010919e.htm.
251. www.theglobalfund.org/en/structures/?lang=en.
252. www.pepfar.gov/about/index.htm.
253. www.clintonfoundation.org/what-we-do/clinton-hiv-aids-initiative/.
254. N Homedes1 and A Ugalde, ‘Multisource drug policies in Latin America: survey of 10 countries’ (2005) 83 (1) Bulletin of the World Health Organization 64-71.
255. http://new.paho.org/hq/index2.php?option=com_docman&task=doc_view&gid=312&Itemid=646.
256. www.wto.org/English/tratop_e/trips_e/factsheet_pharm03_e.htm.
257. www.who.int/trade/glossary/story034/en/index.html.
258. Chien, Colleen. 2007. “HIV/AIDS Drugs for Sub-Saharan Africa: How do brand and generic supply compare?" PLoS ONE, issue 3, e278.
259. K Kubo and H Yamane, ‘Determinants of antiretroviral drug prices: An analysis of Global Price Reporting Mechanism (GPRM) data’, Institute of Development Studies, www.ide.go.jp/English/Publish/Download/Jrp/pdf/jrp_142_05.pdf;
260. http://web.theglobalfund.org/prm/.
261. ‘Determinants of HIV/AIDS Drug Prices for Developing Countries: Analysis of Global Fund Procurement Data’ in H Uchimura (ed) Making Health Services More Accessible in Developing Countries: Finance and Health Resources for Functioning Health Systems (Basingstoke, Palgrave Macmillan 2009) 137-72.
262. R Laing, ‘Procurement, selection, prequalification, pricing and monitoring of medicines’ 16. http://www.wto.org/english/tratop_e/trips_e/techsymp_july10_e/laing_e.pdf.
263. CIPIH Report, 2006, www.who.int/intellectualproperty/documents/thereport/ENPublicHealth Report.pdf, 105-6.
264. www.who.int/impact/en/index.html.
265. ‘Counterfeit definition worrys Pharmas’, Business Standard (New Delhi, 21 May 2008).
266. ‘New counterfeit definition a threat to generics, says India’, SCRIP World Pharmaceutical News (30 May 2008).
267. www.who.int/trade/glossary/story034/en/index.html.
268. J Schott, ‘Comment on the Doha Ministerial’ (2002) 5(1) Journal of International Economic Law (JIEL) 195.
269. C Correa, ‘Implications of the Doha Declaration on the TRIPS Agreement and Public Health’, June 2002 http://www.who.int/medicines/areas/policy/WHO_EDM_PAR_2002.3.pdf viii.
270. FM Abbott, ‘The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO’ (2002) 5(2) JIEL 470.
271. D Ehlermann and L Ehring, ‘The Authoritative Interpretation Under Article IX:2 of the Agreement Establishing the World Trade Organization: Current Law, Practice and Possible Improvements’ (2005) 8(4) JIEL 805.
272. J Jackson, ‘Doha Kakuryou Kaigi no Insho (Impressions from the 4th WTO Ministerial Conference)' (2002) 35(2) Keizai Sangyo Janal (Journal of Economy and Industry) (in Japanese) 12.
273. Chinese Taipei TBR Investigation Report, Compulsory licensing of CD-R patents (January 30, 2008) (hereafter ‘China Taipei TBR Report’), http://trade.ec.europa.eu/doclib/docs/2008/january/tradoc_137633.pdf.
274. Conference Report, ‘Implementation of the Doha Declaration on the TRIPS Agreement and Public Health: Technical Assistance - How to Get It Right’ (28 March 2002) 5, www.haiweb.org/campaign/access/ReportPostDoha.pdf.
275. www.jpo.go.jp/shiryou/toushin/shingikai/pdf/strategy_wg09/file4_3.pdf.
276. www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm.
277. General Council ‘Chairperson’s statement’ at the General Council meeting on 30 August 2003. www.wto.org/english/tratop_e/trips_e/gc_stat_30aug03_e.htm.
278. www.wto.org/english/news_e/pres05_e/pr426_e.htm.
279. www.wto.org/english/tratop_e/trips_e/wtl641_e.htm.
280. www.cptech.org/ip/health/cl/recent-examples.html.
281. www.cptech.org/ip/health/c/mozambique/5apr04-moz-cl.pdf.
282. http://lists.essential.org/pipermail/ip-health/2004-September/006959.html.
283. www.cptech.org/ip/health/c/zambia/zcl.htmlathttp://lists.essential.org/pipermail/ip-health/2004-September/006959.html.
284. www.essentialinventions.org/docs/cameroon/.
285. www.cptech.org/ip/health/cl/Eritrea.png.
286. www.cptech.org/ip/health/cl/recent-examples.html#Malaysia.
287. CP Tech, http://lists.essential.org/pipermail/ip-health/2004-December/007233.html.
288. ICTSD ‘Taiwan Issues Compulsory License for Tamiflu’, http://ictsd.org/i/ip/39838/.
289. www.cptech.org/ip/health/c/thailand/.
290. www.cptech.org/ip/health/cl/recent-examples.html.
291. www.cptech.org/ip/health/c/thailand/thai-cl-clopidogrel_en.pdf.
292. http://portal.saude.gov.br/portal/aplicacoes/noticias/noticias_detalhe.cfm?co_seq_noticia=29719.
293. ‘Ecuador Grants First Compulsory Licence, For HIV/AIDS Drug’, IP Watch (22 April 2010).
294. J Love, CP Tech, ‘Remuneration guidelines for non-voluntary use of a patent on medical technologies’, WHO, Health Economics and Drugs TCM series No 18, www.who.int/medicines/areas/technical_cooperation/WHOTCM2005.1_OMS.pdf.
295. www.wto.org/english/tratop_e/trips_e/amendment_e.htm.
296. http://laws.justice.gc.ca/en/showdoc/cs/P-4/bo-ga:s_21_01//en#anchorbo-ga:s_21_01.
297. www.camr-rcam.gc.ca/index_e.html.
298. www.camr-rcam.gc.ca/intro/regime_e.html.
299. http://www.hemophilia.ca/files/Petition%20House%20of%20Commons%20-%20C-393.pdf.
300. www.apotex.com/global/about/press/20070920.asp, www.news-medical.net/news/20091020/GlaxoSmithKline-to-allow-Apotex-continue-manufacturing-their-drug-in-Rwanda.aspx.
301. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
302. http://www.natcopharma.co.in/solid_tumors.html;
303. http://www.ec21.com/ks-erlotinib-natco/;
304. http://www.star-line.co.jp/a2/chemist/tarceva_erlotinib.html
305. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=SUTENT.
306. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=GLEEVEC.
307. Spicy IP, ‘Natco’s Doha CL Application: Patent Office Rules in Favour of Pfizer’(5 July 2008).
308. ‘Natco’s Doha CL Application: Patent Office Rules in Favour of Pfizer’, Spicy IP, 5 July 2008.
309. ‘Breaking News - Gilead files tenofovir appeal at IPAB’, Spicy IP (7 December 2009)
310. ‘Pfizer to launch free Sutent access programme in Nepal’, Livemint (3 November 2010)
311. T Avafia et al, ‘The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries’ ICTSD, UNCTAD and Tralac, 2006, www.iprsonline.org/unctadictsd/docs/Trade%20and%20Competition%2030%203%2006%20 final%20Edit1%20_2_%20_2_.pdf.
312. MSF - Belgium, ‘Civil Society Movement: To Revoke the Thai Patent on ddI’ (Bangkok, 2004) 3-6.
313. J Reichman et al, ‘Non-voluntary Licensing of Patented Inventions: Historical Perspective, Legal Framework under TRIPS, and an Overview of the Practice in Canada and the United States of America’, UNCTAD/ICTSD Issue Paper No 5, September 2002, 24.
314. JD Sachs and JJ Myers, ‘The End of Poverty: Economic Possibilities for Our Time’, 30 March 2005, www.cceia.org/resources/transcripts/5132.html#1.
315. RA Castellano, ‘Note, Patent Law for New Medical Uses of Known Compounds and Pfizer’s Viagra Patent’ (2006) 46 IDEA 283, 284;
316. I Shirasu, ‘Defense of the Chinese Pharmaceutical Market:the Annulment of the PRB Decision on the Viagra Patent’ (in Japanese) (2006) 4(48) IP Prism 289-290;
317. RC Bird and DR Cahoy, ‘The Impact of Compulsory Licensing on Foreign Direct Investment:A Collective Bargaining Approach’ (2008) 45(2) American Business Law Journal 24.
318. A Allam, ‘Investment, Egypt Tries Patent Laws’, New York Times (4 October 2002), http://www.nytimes.com/2002/10/04/business/worldbusiness/04EGYP.html.
319. www.nytimes.com/2002/10/04/business/worldbusiness/04EGYP.html.
320. Intellectual Property Law, www.egypo.gov.eg/inner/english/PDFs/law2002e.pdf.
321. M Edelman, ‘The Argentine Trade Tango: Out of Step on Intellectual Property Protection’ (1999) 172 AdTI Issue Brief 1-7, hwww.adti. net/new_zuberi_uploaded/IP/Argentine_Trade_Tango.html.
322. S Nakajima, Commentary on the Chinese Patent Law and Regulations Article by Article (in Japanese, Keizai Sangyou Chousakai, 2006) 588.
323. JP Murmann, ‘Chemical Industries after 1850', Oxford Encyclopedia of Economic History (Oxford University Press, 2002);
324. LF Haber, The Chemical Industry 1900-1930: international growth and technological change (Oxford, Clarendon Press, 1971).
325. H Redwood, The Pharmaceutical Industry: trends, problems and achievements (Felixstowe, Oldwicks Press, 1988) 6-35.
326. H Iwata et al, Busshitsu no Chishiki (Knowledge about Product Patents, in Japanese) (Tokyo, Tusho-Sangyo Chosakai, 1975) 3-7.
327. http://ftp.wipo.int/pub/library/ebooks/Internationalconferences-recordsproceedings/LisbonneConference1958/.
328. I Neary, ‘Patent legislation and the Japanese pharmaceutical industry’ (1990) 2(2) Japan Forum 208.
329. P Narayanan, Patent Law, 2nd edn (Calcutta, Eastern Law House, 1985) 5-7.
330. R Ayyangar, Report on the Revision of the Patent Law (New Delhi, 1959) (Ayyangar Report), see also ch 2.
331. AK Bagchi, ‘India Patents Act and Its Relation to Technological Development in India: a Preliminary Investigation’ (1984) Feb. Economic and Political Weekly 291-93.
332. http://ipindia.nic.in/ipr/patent/patents.htm.
333. S Basheer, '“Policy Style” Reasoning at the Indian Patent Office’ (2005) Intellectual Property Quarterly 313.
334. H Redwood, New Horizons in India: Consequences of Pharmaceutical Patient Protection (Felixstowe, Oldwicks Press, 1994) 1.
335. C Correa, ‘Negotiation of A Free Trade Agreement European Union-India: Will India Accept Trips-Plus Protection?' June 2009, http://www.oxfam.de/download/correa_eu_india_fta.pdf 5.
336. S Chaudhuri, The WTO and India’s Pharmaceuticals Industry: Patent Protection, TRIPS, and Developing Countries (New Delhi and New York, Oxford University Press, 2005) 34-36.
337. ‘Patent Protection for New Drug Creation and Criticisms by Developing Country’ (in Japanese) 2006 (10) AIPPI Journal 2-11.
338. H Redwood, Brazil: The Future Impact of Pharmaceutical Patents (Felixstowe, Oldwicks Press, 1995) 3.
339. B Salama and D Benoliel, ‘Pharmaceutical Patent Bargains: The Brazilian Experience’ (February 2009) http://ssrn.com/abstract=1340349, 5-8.
340. JAZ Bermudez and MA Oliveira, Intellectual Property in the Context of the WTO TRIPS Agreement: challenges for public health (Rio de Janeiro, Oswaldo Cruz Foundation, 2004) 153-54.
341. F Orsi et al, ‘Intellectual Property Rights, Anti-AIDS Policy and Generic Drugs: Lessons from the Brazilian Public Health Program,' in J-P Moatti et al (eds), Economics of AIDS and Access to HIV/AIDS Care in Developing Countries, Issues and Challenges (Paris, Agence Nationale de Recherches sur le Sida, 2003).
342. www.wipo.int/clea/en/text_pdf.jsp?lang=EN&id=860
343. www.csptal.com/en/en_z.asp?id=120
344. P Goldstein and J Straus, Intellectual Property in Asia: Law, Economics History and Politics (Heidelberg, Springer, 2009) 38.
345. http://en.wikipedia.org/wiki/Four_Great_Inventions_of_ancient_China#Origins.
346. IP Watch, ‘International Patent Filings Dip in 2009 amid Global Economic Downturn’, 8 February 2010.
347. AV Ganesan, The Implications of the Patents (Amendment) Ordinance, 1999, (New Delhi, Indian Council for Research on International Economic Relations, 1999) Annex I 36-37.
348. FM Scherer, ‘Losing the first mover advantage: India should focus on new drug development to offset the harm, if any’ Times (India) (7 April 2005).
349. FM Scherer and J Watal, ‘Post-TRIPS Options for Access to Patented Medicines in Developing Countries’ (2001) Commission on Macroeconomics and Health, Working Paper Series, Paper No WG 4:1, 15-16.
350. SE Fren et al, ‘India’s health biotech sector at a crossroad’ (2007) 25 Nature Biotechnology.
351. CM Gulhati, Editor, Monthly Index of Medical Specialities (MIMS India), New Delhi, 25 November 2009.
352. www.wipo.int/clea/en/details.jsp?id=547&tab=2.
353. ‘Foreign drug companies may lose exclusivity for some drugs in India’, Pharma China (New Delhi, 5 February 2010).
354. http://lobis.nic.in/dhc/SMD/judgement/15-07-2010/SMD15072010CW35162007.pdf.
355. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/consol_2004/human_code.pdf.
356. T Saiki, ‘On the Relationship between the Pharmaceutical Industry Development and Patent Protection’ (in Japanese) (2003) 13 Chizai Prism.
357. M Sakakibara and L Branstetter ‘Evidence from the 1998 Japanese Patent Law Reforms’ (2001) 32(1) Rand Journal of Economics 77-100.
358. J Mueller, ‘The Tiger Awakens: The Tumultuous Transformation of India’s Patent System and the Rise of Indian Pharmaceutical Innovation’ (2007) 68(3) University of Pittsburgh Law Review 599-600.
359. www.anvisa.gov.br/eng/index.htm.
360. www.abiaids.org.br.
361. P Ganea, ‘The Amended Chinese Patent Law: Implications for Foreign Rights Holders’ (in Japanese) (2010) 80 Institute of Intellectual Property, Tokyo 17.
362. www.mchem.net/.
363. D Friedmann, ‘China’s National IP Strategy 2008: Feasible Commitments Or Road To Nowhere Paved With Good Intentions?' 15 September 2008, www.mondaq.com/article.asp?articleid=66196.
364. C Morel et al, ‘Health Innovation in Developing Countries to Address Diseases of the Poor’, Bellagio Conference on Diseases of Poverty: The Role of Public-Private Partnerships in Developing Countries, 10-13 May 2004. www.sciencemag.org/cgi/reprint/309/5733/401.pdf, 6.
365. ‘First-Ever Drop In Filings Under Patent Cooperation Treaty Seen In 2009', IP Watch (8 February 2010).
366. www.wipo.int/classifications/ipc/en/.
367. http://ep.espacenet.com/advancedSearch?locale=en_EP.
368. Y Li, Imitation to Innovation in China: The Role of Patents in Biotechnology and Pharmaceutical Industries (Cheltenham, Edward Elgar, 2010) 30-42.
369. R de Silva Rodriguez, Biotechnology in Cuba (Tokyo, Centre for Genetic Engineering and Biotechnology (Centro de Ingeniería Genética y Biotecnología, CIGB), 2009)
370. RS Tancer, ‘The Pharmaceutical Industry in Cuba’ (1995) 17(4) Clinical Therapeutics 1-8.
371. E Lopez et al. ‘Taking stock of Cuban biotech’ (2007) 25(11) Nature Biotechnology 1215.
372. EL Mola et al, ‘Biotechnology in Cuba: 20 years of scientific, social and economic progress’ (2006) 13(1) Journal of Commercial Biotechnology.
373. N Homedes et al, ‘The World Bank’s role in shaping pharmaceutical policies in Latin America’, presented at the Fifth World Congress: ‘Investing in Health’, International Health Economics Association, Barcelona (10-13 July 2005);
374. P Grogg, ‘Health - Cuba: Nearly 80 Percent of Medicines Produced Locally’, Inter Press Service (19 March 2001).
375. S Chaudhuri, ‘Ranbaxy Sell-out: Reversal of Fortunes’, Economic & Political Weekly (19 July 2008) 12.
376. K Shiino, ‘Basic Knowledge of India’s Economy’ (in Japanese) (JETRO, 2009) 99.
377. S Miyazawa, ‘Asia-Pacific Committee Report’ (JPMA, November 2006) 3.
378. BioSpectrum India (Bangalore), BioSpectrum Survey 2006, http://biospectrumindia.ciol.com/;
379. S Mani, ‘A Review of Issues with Respect to India’s National System of Innovation’ (2006) http://globelics.org/index.php?module=htmlpages&func=display&pid=12.
380. Government of India, Research and Development Statistics 2004-05, www.nstmis-dst.org/ContentsPage.htm, 29-30.
381. The original data come from the UNESCO Institute for Statistics (UIS), UNESCO, World Development Indicators 2004/2005 (World Bank, 2005).
382. Resilience amid turmoil: Benchmarking IT industry competitiveness 2009', http://global.bsa. org/2009eiu/study/2009_eiu_global.pdf.
383. ‘Glenmark stops oglemilast (GRC 3886) development programme for COPD & asthma with Forest’, 20 May 2010. www.dancewithshadows.com/pillscribe/glenmark-stops-oglemilast-grc3886- development-programme-for-copd-asthma-with-forest/.
384. TC James, Patent Protection and Innovation: Section 3(d) of the Patents Act and Indian Pharmaceutical Industry (Mumbai, Indian Pharmaceutical Alliance, c/o Vision Consulting Group, 2009) (‘TC James Report’) 28 (see also ch 12).
385. E Penrose, ‘International Patenting and the Less-Developed Countries’ (1973) 83 The Economic Journal 770.
386. www.china.org.cn/english/China/208356.htm.
387. www.sipo.gov.cn/sipo_English/laws/developing/200904/t20090414_450778.html.
388. C Grace, The Effect of Changing Intellectual Property on Pharmaceutical Industry Prospects in India and China: Considerations for Access to Medicines (DFID Health Systems Resource Centre, 2004) 44.
389. www.simm.ac.cn/English/English.htm;
390. www.simm.ac.cn/index.html.
391. www.buyusa.gov/china/en/pharmaceuticals.html.
392. H Redwood, Brazil: The future impact of pharmaceutical patents (Felixstowe, Oldwicks Press, 1995) 55.
393. H Thorsteinsdóttir et al, ‘Different Rhythms of Health Biotechnology Development in Brazil and Cuba’ (2005) 2(3) Journal of Business Chemistry www.businesschemistry.org at 104;
394. B Salama et al, ‘Pharmaceutical Patent Bargains: the Brazilian Experience’, http://works. bepress.com/bruno_meyerhof_salama/45/23-32.
395. Espicom Business Intelligence, The World Generic Market Report 2003 (Chichester, Espicom Business Intelligence, 2002) 20-23.
396. ‘Generic Drugs Market in Brazil Report 2007: 2011 Examines the Chief Reasons Why All Major Generic Players Are Heading to Brazil to Manufacture and Sell Their Drugs’, Business Wire (Dublin/Brazil, 9 December 2007).
397. SO Schweitzer, Pharmaceutical Economics and Policy, 2nd edn (New York, Oxford University Press, 2007) 3-17, 141-54.
398. WHO, The World Medicines Situation (Geneva, WHO, 2004).
399. WHO-WIPO-WTO Joint Technical Symposium, Access to medicines: pricing and procurement practices (Geneva, 16 July 2010) http://www.wto.org/english/tratop_e/trips_e/techsymp_july10_e/techsymp_july10_e.htm
400. WHO, Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and Beyond (Geneva, WHO, 2006) 19.
401. ‘China Puts Healthcare at the Top of the Agenda’ Medical News Today (1 November 2007).
402. J Balzano and J Ping, ‘Coming out of Denial: An Analysis of Aids Law and Policy in China (1987-2006)' (2006) 3(2) Loyola International Law Review 188-90.
403. Source: WHO, www.who.int/hiv/HIVC P_IND.pdf.
404. T Kuroki, ‘Medical Supplies Systems in India’ (in Japanese) (7 August 2007). www.yakuji. co.jp/entry3281.html.
405. WHO, ‘Health Workforce, Infrastructure, Essential Medicines’, World Health Statistics (Geneva, WHO, 2009).
406. ‘Foreign drug companies may lose exclusivity for some drugs in India’, Pharma China (New Delhi, 5 February 2010).
407. C Grace, The Effect of Changing Intellectual Property on Pharmaceutical Industry Prospects in India and China (London, DFID, 2004) 14.
408. AS Nunn et al, ‘Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment’ (2007) www.hsph.harvard.edu/pihhr/files/NunnPlos.pdf, 7.
409. www.v-brazil.com/government/laws/constitution.html.
410. www.unicef.org/infobycountry/brazil_statistics.html.
411. S Mendis et al, ‘The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries’ (2007) 85(4) Bulletin of the World Health Organization.
412. UNCTAD-ICTSD, The Resource Book on TRIPS and Development (Cambridge University Press, 2005 - hereafter Resource Book).
413. J Barton, ‘Reforming the patent system’, 287 (2000) Science 1933-1934.
414. ‘Don’t destabilise or create uncertainty on the IPR regime’, The Hindu (3 August 2007);
415. ‘Innovation Policy Needs National Focus, Use of TRIPS Obligations, Panelists Say’, IP Watch (20 July 2009).
416. S J R Bostyn, ‘Patenting DNA sequences (polynucleotides) and scope of protection in the European Union: an evaluation’ (2004) (European Commission; Directorate-General for Research Food Quality and Safety, 2004) 12.
417. Commission on Intellectual Property Rights, Integrating Intellectual Property Rights and Development Policy (London, CIPR, 2002). www.iprcommission.org/papers/pdfs/final_report/CIPRfullfinal.pdf
418. MS Butler, ‘The role of natural product chemistry in drug discovery’ (2004) 67 Journal of Natural Product (J Nat Prod) 2148.
419. DJ Newman et al, ‘Natural Products as Sources of New Drugs over the Period 1981-2002' (2003) 66 J Nat Prod 1022
420. DJ Abraham (ed), Burger’s Medicinal Chemistry and Drug Discovery, 6th edn (New York, John Wiley, 2003) vol 1 (Drug Discovery) 848.
421. J Michel and B Bettels, ‘Patent citation analysis’ (2001) 51(1) Scientometrics 185-201;
422. Tamada et al, ‘Science Linkages in Technologies Patented in Japan’ (2004) RIETI Discussion Paper Series 04-E-034 (1993-Oct 2001 data over 650,000 patents).
423. AB Jaffe et al, ‘Geographic localization of knowledge spillovers as evidenced by patent citations’ (1993) 108 Quarterly Journal of Economics 577-98.
424. B Tempest, ‘A structural change in the global pharmaceutical marketplace’ (2010) 7(2) Journal of Generic Medicines 117.
425. www.sipf.se/read/PharmaceuticalPatents.pdf.
426. PW Grubb, Patents for Chemicals, Pharmaceuticals and Biotechnology; Fundamentals of Global Law, Practice and Strategy, 4th edn (Oxford University Press, 2004) 217-18.
427. CIPIH Report http://www.who.int/intellectualproperty/report/en/at 216.
428. www.egagenerics.com/gen-evergrn.htm.
429. European Commission, Competition DG, EU Pharmaceutical Sector Inquiry: Final Report (Staff Working Paper), 8 July 2009; http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.html.
430. http://ec.europa.eu/competition/consultations/2009_pharma/index.html.
431. S Seth and K Kara, ‘Product switching in the pharmaceutical industry: Ripe for antitrust scrutiny?' (2010) 7(2) Journal of Generic Medicines 119-30(12).
432. J Leibowitz, ‘Tales from the crypt episodes '08 and '09: The return of section 5 (Unfair methods of competition in commerce are hereby declared unlawful)', FTC section 5 workshop (17 October 2008)
433. M Angel, The Truth About the Drug Companies: How They Deceive Us and What to Do about It, (New York, Random House, 2004) 173-92.
434. RA Bouchard, MD, ‘I’m Still Your Baby: Canada’s Continuing Support of U.S. Linkage Regulations For Pharmaceuticals’ http://works.bepress.com/cgi/viewcontent.cgi?article=1000&context=ron_ bouchard.
435. http://ec.europa.eu/competition/consultations/2009_pharma/hirokoyamane.pdf.
436. http://patentcircle.blogspot.com/2009/02/minor-modification-structural_19.html.
437. S Chaudhuri, ‘TRIPS Agreement and Amendment of Patents Act in India,' Economic and Political Weekly (10 August 2002).
438. ‘Scrap Mashelkar Report, Demand Scientists, NGOs’, The Hindu (3 April 2007).
439. http://www.patentoffice.nic.in/RevisedReport_March2009.doc
440. R Cooper-Dreyfuss and AF Lowenfeld, ‘Two Achievements of the Uruguay Round: Putting TRIPS and Dispute Settlement Together’ (1997) Winter Virginia Journal of International Law 307-08.
441. S Ladas, Patents, Trademarks & Related Rights: National & International Protection (Cambridge MA, Harvard University Press, 1975) vol III 1686.
442. JJ Gorlin, An analysis of the Pharmaceutical-related Provisions of the WTO TRIPS (IP) Agreement (Washington DC, IP Institute, 1999);
443. M Bronckers and P Ondrusek, ‘Protection of Regulatory Data in the EU and WTO Law’ (2005) 8(5) Journal of World Intellectual Property 594.
444. A Taubman, ‘Unfair competition and the financing of public-knowledge goods: the problem of test data protection’ (2008 3(9) Journal of Intellectual Property Law & Practice 601.
445. www.cdsco.nic.in/html/Drugs&CosmeticAct.pdf. Amended in June 2005.
446. ‘Govt To Consider Data Protection’, The Economic Times (29 November 2003).
447. ‘China and India tell a tale of two CMO markets’, SCRIP (30 April 2010) 28.
448. R Dinca, ‘The “Bermuda Triangle” of Pharmaceutical Law: Is Data Protection a Lost Ship?' (2005) 8(4) Journal of World Intellectual Property 517-63.
449. H Bale ‘Drug, Textile Makers to Fight Trade Pact’, Journal of Commerce (8 January 1992). See chp 4.
450. J Watal ‘US - China Intellectual Property Dispute - A Comment on the Interpretation of the TRIPS Enforcement Provisions’ (2010) 5 The Journal of World Intellectual Property 607.
451. B Arnold, CBO Microeconomic and Financial Studies Division, ‘The Pros and Cons of Pursuing Free-Trade Agreements’ (Economic and Budget Issue Brief, A series of issue summaries from the Congressional Budget Office), 31 July, 2003. www.cbo.gov/doc.cfm?index=4458&type=0.
452. http://www.ustr.gov/trade-agreements/free-trade-agreements.
453. www.ftaa-alca.org/alca_e.asp.
454. Business Software Alliance, 2008 BSA Year in Review (Washington DC, BSA, 2009) 10-11.
455. http://w3.bsa.org/eupolicy/Copyright-and-Intellectual-Property.cfm
456. www.eabc.org/media/bsa-eabc_position_on_drm_and_levies.html.
457. www.ustr.gov/sites/default/files/uploads/agreements/fta/colombia/asset_upload_file605_9835.pdf.
458. P Samuelson and S Scotchmer, ‘The Law and Economics of Reverse Engineering’ (2002) 111(7) Yale Law Journal 1639-49.
459. N Pires de Carvalho, The TRIPS Regime of Patent Rights (3rd edn) (Alphen aan den Rijn, Kluwer Law International, 2010) 80-83.
460. www.twnside.org.sg/title2/FTAs/Intellectual_Property/IP_and_Access_to_Medicines/TradeAgreementsandAccesstoMedicationsUnderTheBushAdmini.pdf.
461. www.iprcommission.org/graphic/documents/final_report.htm.
462. www.mofat.go.kr/mofat/fta/eng_0707/2E66(e).pdf.
463. http://waysandmeans.house.gov/Media/pdf/110/05%2014%2007/05%2014%2007.pdf.
464. http://www.ustr.gov/sites/default/files/uploads/agreements/fta/peru/asset_upload_file719_9535.pdf
465. http://www.ustr.gov/sites/default/files/uploads/agreements/fta/colombia/asset_upload_file953_10182.pdf
466. D Vivas-Eugui and M J Oliva, ‘Biodiversity Related Intellectual Property Provisions in Free Trade Agreements’, ICTSD, Issue Paper No.4, 2010) 6.
467. P Roffe and D Vivas, ‘A Case Study on IP Technical Assistance in FTA’, April 2007, ICTSD Issue Paper No 19, 2.
468. www.who.int/phi/documents/RDFinancingwithISBN.pdf.
469. B Tempest, ‘A structural change in the global pharmaceutical marketplace’ (2010) 7(2) Journal of Generic Medicines 115.
470. HG Grabowski and YR Wang ‘The quantity and quality of worldwide new drug introductions, 1982-2003' (2006) 25(2) Health Affairs.
471. JA Schumpeter, Capitalism, Socialism and Democracy (London, Routledge, 1994; originally published by Allen & Unwin, 1942).